Clinical Trials
13 trialsNCT00017433 2020-10-06
Arsenic Trioxide in Treating Patients With Multiple Myeloma
CTI BioPharma
Phase 2 Terminated
NCT00017069 2020-10-05
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
CTI BioPharma
Phase 2 Terminated
NCT00020969 2020-10-05
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Phase 2 Terminated
NCT00104806 2018-08-10
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Wake Forest University Health Sciences
Phase 2 Terminated
NCT00118196 2018-05-11
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Phase 2 Terminated
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00582400 2016-02-19
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The University of Texas Medical Branch, Galveston
Phase 2 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00184054 2014-07-25
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
University of Southern California
Phase 2 Terminated
NCT00061958 2013-01-23
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00006092 2012-09-26
Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00005595 2012-06-11
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease
Northwestern University
Phase 2 Terminated
NCT00227682 2012-05-28
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
OHSU Knight Cancer Institute
Phase 2 Terminated